Why UBS thinks this is the time to buy CSL Limited (ASX:CSL) shares

The sell-off in this market darling may be over with CSL Limited's (ASX: CSL) share price enjoying its second consecutive day of gains as UBS upgrades the stock.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The sell-off of this market darling may be over with CSL Limited's (ASX: CSL) share price enjoying its second consecutive day of gains as UBS upgrades the stock to "buy" from "neutral".

The stock is outperforming the flat S&P/ASX 200 (Index:^AXJO) (ASX: XJO) index this morning as it is rallying 0.9% higher to $192.67 but is still down 16% from its September peak.

It's not the only healthcare stock that's running ahead at the time of writing though. The Cochlear Limited (ASX: COH) share price and RESMED/IDR UNRESTR (ASX: RMD) share price are also making big gains, although CSL is the only one in the sector scoring an upgrade from UBS.

Why the upgrade?

The broker made the recommendation upgrade after reviewing the latest results from CSL's competitors Shire and Grifols Bioscience.

It believes that CSL's immunoglobulin (IG) portfolio continues to grow faster than the rest of the market and that the company can generate a compound annual growth rate (CAGR) of around 11% over the next three years.

That means its forecast price-earnings (P/E) multiple of around 30 times isn't unwarranted even though that's nearly double the P/E of the S&P/ASX 200.

However, the broker has lowered its earnings per share (EPS) forecast on the stock by around 6% due in part to changes in its exchange rate assumptions, and that has resulted in a drop in its price target for CSL to $220 from $232 per share.

That still leaves plenty of upside for the stock, which had crashed to a six-month low of $174.69 just two weeks ago as high P/E stocks took the brunt of the October market sell-off.

"CSL is trading on a 12-mth forward PE of 30.2x, a 97% premium to the ASX200, compared to 2-year averages of 29.7x and 87% respectively," said UBS.

"On a PE vs 2-year forward EPS growth basis, it screens favourably relative to a basket of listed Australian healthcare companies. Our DCF-based valuation of A$220 is arguably a better reflection of inherent value noting sustained EPS growth forecasts over the longer term."

There's plenty to like about CSL given its strong track record in generating shareholder returns. I rate this as one of the most admired stocks on the market along with Macquarie Group Ltd (ASX: MQG).

Foolish Takeaway

While I think CSL has probably seen the bottom in this cycle, I am more inclined to buy value stocks in anticipation of the next market upswing as we approach the end of the calendar year.

Looking for other blue-chip stock ideas as we head into the "Santa Rally" season? The experts at the Motley Fool have picked their best blue-chip stock ideas and you can find out what these are for free by following the link below.

Motley Fool contributor Brendon Lau owns shares of Macquarie Group Limited. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Market up or down
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the week...

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Share Gainers

4 ASX 200 shares racing ahead of the benchmark this week

ASX investors sent these four stocks soaring 12% to 18% this week. But why?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why BHP, Coronado Global, EBR Systems, and Whitehaven Coal shares are pushing higher today

These shares are ending the week on a positive note. Let's find out why.

Read more »

a young woman looks happily at her phone in one hand with a selection of shopping bags in her other hand.
BNPL shares

Up 87% since April, why the Zip share price can keep flying higher into 2026

A leading fund manager expects more outsized gains from Zip shares ahead.

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a miserly session for investors today.

Read more »

Happy coal miner.
Share Gainers

Up 75% this week, why is this ASX All Ords stock rocketing again today?

Investors are piling into this ASX 300 stock on Wednesday. But why?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a bountiful session for investors this hump day.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Share Gainers

Why Coronado, DroneShield, Lovisa, and Mayne Pharma shares are racing higher today

These shares are having a good time on hump day. But why?

Read more »